Search Results - Filip, Janku

Refine Results
  1. 1
    Tumor heterogeneity in the clinic: is it a real problem?

    Tumor heterogeneity in the clinic: is it a real problem? by Filip Janků

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

    Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients by Filip Janků

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

    Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? by Jiří Polívka, Martin Pešta, Filip Janků

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)

    Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) by Hazem El‐Osta, Filip Janků, Razelle Kurzrock

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

    Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening by Jacob J. Adashek, Filip Janků, Razelle Kurzrock

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Erdheim-Chester Disease: Characteristics and Management

    Erdheim-Chester Disease: Characteristics and Management by Javier Muñoz, Filip Janků, Philip R. Cohen, Razelle Kurzrock

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia

    STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia by Javier Muñoz, Navjot Dhillon, Filip Janků, Stephanie S. Watowich, David S. Hong

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    The mu opioid receptor: A new target for cancer therapy?

    The mu opioid receptor: A new target for cancer therapy? by Patrick A. Singleton, Jonathan Moss, Daniel D. Karp, Johnique T. Atkins, Filip Janků

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer by Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

    Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing by Filip Janků, Ahmed O. Kaseb, Apostolia M. Tsimberidou, Robert A. Wolff, Razelle Kurzrock

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer

    Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer by Filip Janku, Lorraine Johnson, Daniel D. Karp, Johnique T. Atkins, Patrick A. Singleton, J. Moss

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes by Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    ALK fusions in the pan-cancer setting: another tumor-agnostic target?

    ALK fusions in the pan-cancer setting: another tumor-agnostic target? by Aditya Shreenivas, Filip Janků, Mohamed A. Gouda, Hui‐Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Challenges and perspective of drug repurposing strategies in early phase clinical trials

    Challenges and perspective of drug repurposing strategies in early phase clinical trials by Shumei Kato, Stacy L. Moulder, Naoto T. Ueno, Jennifer J. Wheler, Funda Meric‐Bernstam, Razelle Kurzrock, Filip Janků

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

    BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes by Hazem El‐Osta, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Kevin Kim, Sijin Wen, Filip Janků, Razelle Kurzrock

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center by Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers by Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

    A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies by John W. Moroney, Matthew Schlumbrecht, Thorunn Helgason, Robert L. Coleman, Stacy Moulder, Aung Naing, Diane C. Bodurka, Filip Janků, David S. Hong, Razelle Kurzrock

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors by Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors by Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: